Want to see JP:3386 full AI Analyst Report?
Cosmo Bio Co., Ltd. (3386) Stock Price & Analysis
3386 Stock Chart & Stats
- Day’s Range
- JPY 1,228.00 - JPY 1,236.00
- 52-Week Range
- JPY 1,083.00 - JPY 1,486.00
- Previous Close
- JPY 1,227.00
- Volume
- 2,500
- Average Volume (3M)
- 3,507
- Market Cap
- JPY 7.16B
- Enterprise Value
- JPY 4.26B
- Total Cash (Recent Filing)
- JPY 4.07B
- Total Debt (Recent Filing)
- JPY 737.00M
- Price to Earnings (P/E)
- 19.3
- Beta
- 0.30
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Dec 29, 2026
- Dividend Yield
- 4.05%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Extremely low debt relative to equity provides durable financial flexibility: supports investment in R&D, inventory and distribution, buffers cyclical revenue swings, and reduces refinancing risk—strengthening the company's ability to fund operations and strategic moves over the next 2–6 months.
Rebounding Cash Generation
A meaningful recovery in operating and free cash flow increases internal funding capacity for capex, working capital and shareholder returns. Sustained positive cash conversion supports durable operational resilience and reduces reliance on external financing over the medium term.
Diversified Product & Distribution Model
A broad catalog plus both manufacturing and distribution channels creates recurring consumable demand, multiple revenue streams (product, agency, and service), and strong customer stickiness within academic and pharma R&D—supporting stable revenue and margin opportunities over time.
Bears Say
Margin Compression
Significant decline in profitability versus 2020–2021 suggests structural margin pressure from pricing, mix, or cost increases. If margins do not recover, earnings power and return metrics will remain constrained despite revenue growth, limiting free cash expansion and ROE recovery.
Volatile Cash Flow History
Large year-to-year swings in free cash flow indicate sensitivity to working capital, project timing or one-offs. This volatility reduces predictability of internally funded investments and dividends, and raises execution risk for multi-quarter initiatives.
Weakened Shareholder Returns (ROE)
A sharp drop in ROE signals the company is generating much lower returns on equity capital. Persistently weak ROE can constrain capital allocation options, reduce investor confidence, and imply structural challenges in restoring profitability to prior levels.
3386 FAQ
What was Cosmo Bio Co., Ltd.’s price range in the past 12 months?
What is Cosmo Bio Co., Ltd.’s market cap?
When is Cosmo Bio Co., Ltd.’s upcoming earnings report date?
How were Cosmo Bio Co., Ltd.’s earnings last quarter?
Is Cosmo Bio Co., Ltd. overvalued?
Does Cosmo Bio Co., Ltd. pay dividends?
What is Cosmo Bio Co., Ltd.’s EPS estimate?
How many shares outstanding does Cosmo Bio Co., Ltd. have?
What happened to Cosmo Bio Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cosmo Bio Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cosmo Bio Co., Ltd.
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Norihiko Shibayama
- Employees
- 182
- Website
- www.cosmobio.com
- Address
- Toyo-Ekimae Building, Tokyo, TY, 135-0016, JP
Cosmo Bio Co., Ltd. (3386) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 4 | 0 | 8 |